[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380450-105":59,"doc-detail-380450-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","precision-medicine-in-the-era-of-multi-omics-can-the-data-tsunami-guide-rational-treatment-decision","Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?","","Cancer precision medicine integrates multiple biological dimensions to model patient-specific tumor progression under evolving selection pressures. With multiple drivers per tumor and diverse genomic alterations emerging at treatment failure, drug sensitivity depends on target actionability, clonal or subclonal origin, and coexisting changes. Effective therapy prioritization requires ranking alterations by proven actionability, while accounting for spatial and temporal heterogeneity. High-throughput genomics and artificial intelligence are highlighted to analyze complex datasets and shape rational treatment decisions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/precision-medicine-in-the-era-of-multi-omics-can-the-data-tsunami-guide-rational-treatment-decision/380450/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/precision-medicine-in-the-era-of-multi-omics-can-the-data-tsunami-guide-rational-treatment-decision/380450.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What determines whether a drug target is actionable for precision medicine decisions?","Question",{"text":112,"@type":113},"Drug sensitivity depends on the actionability of the target, its clonal or subclonal origin, and coexisting genomic alterations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why does multi-driver tumor biology complicate treatment choice?",{"text":117,"@type":113},"Multiple drivers per tumor create several treatment options, so clinical decision-making must account for which alterations are truly actionable.",{"name":119,"@type":110,"acceptedAnswer":120},"How do high-throughput genomics and AI contribute to future precision medicine?",{"text":121,"@type":113},"High-throughput genomics enables rapid assessment of large numbers of genes, while AI algorithms are positioned to become indispensable for thorough analysis of abundant complex biological data.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380450,1790880898,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","REVIEW  \nPrecision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?  \nM. Aldea1 , 2􀀁, L. Friboulet2, S. Apcher2, F. Jaulin2, F. Mosele1 , 2, T. Sourisseau2, J.-C. Soria3 , 4, S. Nikolaev2 & F. André1, 2, 3 1Department of Medical Oncology, Gustave Roussy, Villejuif; 2PRISM, INSERM, Gustave Roussy, Villejuif; 3Paris Saclay University, Orsay; 4Drug Development Department, Gustave Roussy, Villejuif, France  \nAvailable online xxx  \nPrecision medicine for cancer is rapidly moving to an approach that integrates multiple dimensions of the biology in order to model mechanisms of cancer progression in each patient. The discovery of multiple drivers per tumor challenges medical decision that faces several treatment options. Drug sensitivity depends on the actionability of the target, its clonal or subclonal origin and coexisting genomic alterations. Sequencing has revealed a large diversity of drivers emerging at treatment failure, which are potential targets for clinical trials or drug repurposing. To effectively prioritize therapies, it is essential to rank genomic alterations based on their proven actionability. Moving beyond primary drivers, the future of precision medicine necessitates acknowledging the intricate spatial and temporal heterogeneity inherent in cancer. The advent of abundant complex biological data will make artificial intelligence algorithms indispensable for thorough analysis. Here, we will discuss the advancements brought by the use of high-throughput genomics, the advantages and limitations of precision medicine studies and future perspectives in this field.  \nKey words: precision medicine, ESCAT, OncoKB, NGS, high-throughput genomics  \nINTRODUCTION  \nMore than a century ago, the physician and scientist Paul Ehrlich described for the first time the concept of finding a‘magic bullet’ that is able to hit a specific target to kill the disease, while sparing the rest of the body. From the development of endocrine therapy that is the ‘first-generation bullet’ in oncology, we now have reached an era where treatments are designed to selectively target drivers of tumorigenesis, and tailored according to the dynamic tumor evolution. Precision medicine includes the research and validation of predictive, prognostic and resistance biomarkers, but also predictors of toxicity, that help medical decisions and tailor treatment.1 Precision medicine has notably changed the paradigm of treatment in certain cancer types. The discovery of ‘drugetarget’ pairs, such asimatinib in chronic myeloid leukemia with BCR-ALB1 fusions,2 gefitinib in epidermal growth factor receptor (EGFR) -mutated non-small-cell lung cancer (NSCLC)3 and vemurafenib in BRAF-mutated melanoma,4 was the first proof that  \n*Correspondence to: Dr Mihaela Aldea, Department of Medical Oncology, Gustave Roussy, 114 Edouard Vaillant street, Villejuif 94805, France. Tel: þ33 1 42 11 42 11  \n[E-mail:](E-mail: mihaela.aldea@gustaveroussy.fr)[ mihaela.aldea@gustaveroussy.fr](E-mail: mihaela.aldea@gustaveroussy.fr) (M. Aldea).  \n2059-7029/© 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \ntargeted therapy could improve patients’ outcomes and quality of life. Currently, there are >20 biomarkers routinely assessed in clinical practice for the administration of approved targeted therapies (Figure 1) .  \nOver the last decades, there has also been a tremendous progress of molecular techniques, from capillarybased sequencing technologies to next-generation sequencing (NGS), a modern massive parallel sequencing.5, 6 High-throughput sequencing enables a rapid assessment of hundreds or thousands of genes from small DNA quantities.7 It may sequence targeted panels of genes (targeted sequencing), the whole exome (wholeexome sequencing, WES) ","cbCainnpzCRb0sUY","https://ap.wps.com/l/cbCainnpzCRb0sUY","pdf",1127801,15,"English","# Introduction\n# Clinical trials of precision medicine investigating clinical utility of high-throughput genomics to detect genomic drivers","[{\"question\":\"What determines whether a drug target is actionable for precision medicine decisions?\",\"answer\":\"Drug sensitivity depends on the actionability of the target, its clonal or subclonal origin, and coexisting genomic alterations.\"},{\"question\":\"Why does multi-driver tumor biology complicate treatment choice?\",\"answer\":\"Multiple drivers per tumor create several treatment options, so clinical decision-making must account for which alterations are truly actionable.\"},{\"question\":\"How do high-throughput genomics and AI contribute to future precision medicine?\",\"answer\":\"High-throughput genomics enables rapid assessment of large numbers of genes, while AI algorithms are positioned to become indispensable for thorough analysis of abundant complex biological data.\"}]","Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? | PDF",1790240242,38]